Targeting PGM3 as a Novel Therapeutic Strategy in <i>KRAS/LKB1</i> Co-Mutant Lung Cancer

Targeting PGM3 as a Novel Therapeutic Strategy in <i>KRAS/LKB1</i> Co-Mutant Lung Cancer

In non-small-cell lung cancer (NSCLC), concurrent mutations in the oncogene <i>KRAS</i> and tumor suppressor <i>STK11</i> (also known as LKB1) confer an aggressive malignant phenotype, an unfavourability towards immunotherapy, and overall poor prognoses in patients. In a prev...

Full description

Bibliographic Details
Main Authors: Hyunmin Lee, Feng Cai, Neil Kelekar, Nipun K. Velupally, Jiyeon Kim
Format: Article
Language:English
Published: MDPI AG 2022-01-01
Series:Cells
Subjects:
cancer metabolism
metabolic vulnerability
non-small cell lung cancer
<i>KRAS</i> and <i>LKB1</i> co-mutations
the hexosamine biosynthesis pathway
glycosylation
Online Access:https://www.mdpi.com/2073-4409/11/1/176

Internet

https://www.mdpi.com/2073-4409/11/1/176

Similar Items